BR112018076005A2 - anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral - Google Patents
anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateralInfo
- Publication number
- BR112018076005A2 BR112018076005A2 BR112018076005-6A BR112018076005A BR112018076005A2 BR 112018076005 A2 BR112018076005 A2 BR 112018076005A2 BR 112018076005 A BR112018076005 A BR 112018076005A BR 112018076005 A2 BR112018076005 A2 BR 112018076005A2
- Authority
- BR
- Brazil
- Prior art keywords
- apoptosis
- monitoring
- gel
- monoclonal antibody
- glutamyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 230000006907 apoptotic process Effects 0.000 title abstract 5
- 238000012544 monitoring process Methods 0.000 title abstract 4
- 239000004472 Lysine Substances 0.000 title abstract 3
- 206010040047 Sepsis Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000003018 immunoassay Methods 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a um método ex vivo para o monitoramento de apoptose que é baseado na detecção de gama-glutamil-l-epsilon-lisina (ggel) livre em uma amostra biológica de um indivíduo com um anticorpo monoclonal específico para ggel. a invenção também se refere ao anticorpo monoclonal específico para ggel, bem como a kits de diagnóstico contendo tal ligante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305724.3 | 2016-06-14 | ||
EP16305724 | 2016-06-14 | ||
PCT/EP2017/064553 WO2017216227A1 (en) | 2016-06-14 | 2017-06-14 | Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018076005A2 true BR112018076005A2 (pt) | 2019-03-26 |
Family
ID=56263635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018076005-6A BR112018076005A2 (pt) | 2016-06-14 | 2017-06-14 | anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral |
Country Status (9)
Country | Link |
---|---|
US (1) | US11242408B2 (pt) |
EP (1) | EP3469371A1 (pt) |
JP (1) | JP7036751B2 (pt) |
CN (1) | CN109313201B (pt) |
BR (1) | BR112018076005A2 (pt) |
CA (1) | CA3027452A1 (pt) |
IL (1) | IL263517B2 (pt) |
WO (1) | WO2017216227A1 (pt) |
ZA (1) | ZA201807854B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022539038A (ja) * | 2019-06-27 | 2022-09-07 | ヴェルソー セラピューティクス, インコーポレイテッド | 骨髄細胞炎症性表現型を調節するための抗lrrc25組成物及び方法、ならびにその使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0873500A (ja) * | 1994-09-01 | 1996-03-19 | Ajinomoto Co Inc | ε−(γ−グルタミル)リジン架橋部位に対するモノクローナル抗体及び免疫学的測定法 |
US5750360A (en) * | 1995-06-07 | 1998-05-12 | Lxr Biotechnology Inc. | Method for quantitatively measuring apoptosis |
KR100259828B1 (ko) * | 1995-09-11 | 2000-06-15 | 히라타 다다시 | 인체 인터루킨 5 수용체 알파-사슬에 대한 항체 |
JPH09328425A (ja) * | 1996-04-12 | 1997-12-22 | Hayashibara Biochem Lab Inc | アポトーシス調節剤 |
JP2005106694A (ja) * | 2003-09-30 | 2005-04-21 | Mochida Pharmaceut Co Ltd | 敗血症早期検出及び重篤度評価 |
KR101213015B1 (ko) * | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
US8377701B2 (en) * | 2008-04-27 | 2013-02-19 | H. Lundbeck A/S | Specific ligands to sortilin |
FR2983492B1 (fr) * | 2011-12-06 | 2015-10-30 | Advanced Biodesign | Procede ex vivo de purge tumorale d'un echantillon biologique |
UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
-
2017
- 2017-06-14 BR BR112018076005-6A patent/BR112018076005A2/pt unknown
- 2017-06-14 JP JP2018566396A patent/JP7036751B2/ja active Active
- 2017-06-14 CN CN201780037081.4A patent/CN109313201B/zh active Active
- 2017-06-14 WO PCT/EP2017/064553 patent/WO2017216227A1/en unknown
- 2017-06-14 US US16/309,860 patent/US11242408B2/en active Active
- 2017-06-14 CA CA3027452A patent/CA3027452A1/en active Pending
- 2017-06-14 EP EP17731527.2A patent/EP3469371A1/en active Pending
-
2018
- 2018-11-21 ZA ZA2018/07854A patent/ZA201807854B/en unknown
- 2018-12-05 IL IL263517A patent/IL263517B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20190169313A1 (en) | 2019-06-06 |
JP7036751B2 (ja) | 2022-03-15 |
JP2019529335A (ja) | 2019-10-17 |
ZA201807854B (en) | 2019-07-31 |
WO2017216227A1 (en) | 2017-12-21 |
IL263517B (en) | 2022-10-01 |
IL263517B2 (en) | 2023-02-01 |
CN109313201B (zh) | 2022-04-01 |
US11242408B2 (en) | 2022-02-08 |
CN109313201A (zh) | 2019-02-05 |
CA3027452A1 (en) | 2017-12-21 |
IL263517A (en) | 2019-02-03 |
EP3469371A1 (en) | 2019-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
EA201400491A1 (ru) | Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения | |
AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
BR112017017076A2 (pt) | inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre. | |
MX2020001193A (es) | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. | |
BR112014032326A2 (pt) | caracterização de amostra de fluido heterogêneo | |
EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
BR112016010106A2 (pt) | ensaios para igfbp7 com melhor desempenho em amostras biológicas | |
BR112016007037A2 (pt) | método para detectar câncer pancreático, anticorpo monoclonal e kit | |
PE20160657A1 (es) | Composiciones y metodos para identificar un riesgo de cancer en un sujeto | |
AR071034A1 (es) | Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
BR112016002668A2 (pt) | métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares | |
BR112017011026A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
BR112022011676A2 (pt) | Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método | |
BR112018010764A2 (pt) | método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente | |
ES2540255A1 (es) | Método de aislamiento de cuerpos apoptóticos | |
BR112014031958A2 (pt) | bag3 como marcador de tecido e soro bioquímico | |
BR112018069316A2 (pt) | métodos para detectar presença de pelo menos uma espécie de bordetella patogênica e selecionar um paciente que exibe sintomas semelhantes à coqueluche, e, kit para detectar presença de pelo menos uma espécie de bordetella patogênica. | |
BR112016017926A2 (pt) | ensaio para detectar periostina humana | |
BR112018076005A2 (pt) | anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral | |
BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia | |
ES2570609T3 (es) | Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal | |
EA201490576A1 (ru) | Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |